Long non‐coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma

Extramedullary myeloma (EMM) occurs when myeloma develops outside the bone marrow; it often develops after chemotherapy and is associated with the acquisition of chemo‐resistance and a fatal course. The mechanisms underlying extramedullary spread have not yet been fully elucidated. MALAT1 is a highly abundantly and ubiquitously expressed long non‐coding RNA that plays important roles in cancer metastasis. The aims of this study were to clarify the association of MALAT1 with EMM and to elucidate the underlying mechanism of EMM formation under chemotherapeutic pressure. MALAT1 expression was significantly higher in multiple myeloma (MM) than in monoclonal gammopathy of undetermined significance. Furthermore, MALAT1 expression was markedly higher in EMM compared with that in corresponding intramedullary myeloma cells. A higher MALAT1 level was associated with shorter overall and progression‐free survival. MALAT1 expression level was positively correlated with expression of HSP90AA1, HSP90AB1 and HSP90B1 but not with TP53 expression. MALAT1 was significantly upregulated by bortezomib and doxorubicin. Considering the known functions of MALAT1, our results suggest that it acts as a stress response gene that is upregulated by chemotherapy, thereby linking chemotherapy to EMM formation. Elucidating the biological implication of long non‐coding RNA contributes to deeper understanding concerning the pathogenesis and investigation of novel therapeutic targets for MM.

[1]  Li Lin,et al.  Long non-coding RNA MALAT1 promotes gastric cancer tumorigenicity and metastasis by regulating vasculogenic mimicry and angiogenesis. , 2017, Cancer letters.

[2]  Hui Li,et al.  MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression , 2017, Oncotarget.

[3]  G. Calin,et al.  MALAT1 promoted invasiveness of gastric adenocarcinoma , 2017, BMC Cancer.

[4]  L. Du,et al.  MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2 , 2017, Molecular Cancer Therapeutics.

[5]  Fuman Qiu,et al.  Disrupting MALAT1/miR-200c sponge decreases invasion and migration in endometrioid endometrial carcinoma. , 2016, Cancer letters.

[6]  Rui Zhang,et al.  LncRNAs and cancer. , 2016, Oncology letters.

[7]  Hua Li,et al.  Overexpressed MALAT1 promotes invasion and metastasis of gastric cancer cells via increasing EGFL7 expression. , 2016, Life sciences.

[8]  S. Aerts,et al.  p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity , 2016, Nature Medicine.

[9]  X. Sheng,et al.  The Long Noncoding RNA MALAT-1 Is Highly Expressed in Ovarian Cancer and Induces Cell Growth and Migration , 2016, PloS one.

[10]  Z. Zeng,et al.  The Long Noncoding RNA MALAT-1 is A Novel Biomarker in Various Cancers: A Meta-analysis Based on the GEO Database and Literature , 2016, Journal of Cancer.

[11]  Howard Y. Chang,et al.  Long Noncoding RNAs in Cancer Pathways. , 2016, Cancer cell.

[12]  F. Strozzi,et al.  Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma , 2016, Oncotarget.

[13]  Tingting Zhang,et al.  Long Non Coding RNA MALAT1 Promotes Tumor Growth and Metastasis by inducing Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma , 2015, Scientific Reports.

[14]  Haixiu Yang,et al.  Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma , 2015, Journal of experimental & clinical cancer research : CR.

[15]  M. Chiarini,et al.  CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. , 2015, Cell reports.

[16]  Shenglin Ma,et al.  Long Noncoding RNA MALAT-1 Can Predict Metastasis and a Poor Prognosis: a Meta-Analysis , 2015, Pathology & Oncology Research.

[17]  N. Munshi,et al.  Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations , 2015, British journal of haematology.

[18]  L. Qiu,et al.  Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases. , 2015, Clinical lymphoma, myeloma & leukemia.

[19]  I. Kurochkin,et al.  Long noncoding RNAs: a potential novel class of cancer biomarkers , 2015, Front. Genet..

[20]  S. Dhanasekaran,et al.  The landscape of long noncoding RNAs in the human transcriptome , 2015, Nature Genetics.

[21]  N. Munshi,et al.  Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation , 2014, British journal of haematology.

[22]  Y. Toiyama,et al.  Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. , 2014, Carcinogenesis.

[23]  Jan-Gowth Chang,et al.  MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression , 2014, BMC Cancer.

[24]  F. Hou,et al.  Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex , 2014, British Journal of Cancer.

[25]  Yutaka Suzuki,et al.  Long noncoding RNA NEAT1-dependent SFPQ relocation from promoter region to paraspeckle mediates IL8 expression upon immune stimuli. , 2014, Molecular cell.

[26]  S. Ševčíková,et al.  Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse , 2014, Haematologica.

[27]  F. Zhan,et al.  Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib , 2013, Leukemia.

[28]  I. Ghobrial,et al.  Extramedullary multiple myeloma , 2013, Leukemia & lymphoma.

[29]  S. Diederichs,et al.  MALAT1 — a paradigm for long noncoding RNA function in cancer , 2013, Journal of Molecular Medicine.

[30]  D. Spector,et al.  The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. , 2013, Cancer research.

[31]  B. Barlogie,et al.  Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents , 2012, Haematologica.

[32]  Nadav S. Bar,et al.  Landscape of transcription in human cells , 2012, Nature.

[33]  Chaolin Zhang,et al.  The lncRNA Malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. , 2012, Cell reports.

[34]  J. Bladé,et al.  Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  K. Anderson,et al.  Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers , 2011, British journal of haematology.

[36]  Randeep Rakwal,et al.  MALAT‐1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility‐related genes , 2010, FEBS letters.

[37]  J. Wengel,et al.  Locked Nucleic Acids: Promising Nucleic Acid Analogs for Therapeutic Applications , 2010, Chemistry & biodiversity.

[38]  C. Pascutto,et al.  Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  Hong Chang,et al.  p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. , 2009, Leukemia research.

[40]  R. Hayes,et al.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.

[41]  Y. Furukawa,et al.  Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma , 2009, Oncogene.

[42]  Sa A. Wang,et al.  Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma , 2008, European journal of haematology.

[43]  Gonzalez,et al.  Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. , 2003, Blood.

[44]  Michael Thomas,et al.  MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer , 2003, Oncogene.

[45]  A. Olshen,et al.  Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma , 2003, British journal of haematology.

[46]  John Crowley,et al.  Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. , 2002, Blood.

[47]  T. Rasmussen,et al.  Differential expression of CD56 and CD44 in the evolution 
of extramedullary myeloma , 2002, British journal of haematology.

[48]  A. Zou,et al.  Long non-coding RNA MALAT1 is up-regulated in ovarian cancer tissue and promotes SK-OV-3 cell proliferation and invasion. , 2016, Neoplasma.

[49]  J. Wingard,et al.  Extramedullary disease in plasma cell myeloma: the iceberg phenomenon , 2013, Bone Marrow Transplantation.

[50]  D. Spector,et al.  The Noncoding RNA MALAT 1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells , 2013 .

[51]  R. Kyle,et al.  Multiple myeloma. , 2008, Blood.

[52]  H. Johnsen,et al.  Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. , 2005, Blood.

[53]  谷脇 雅史,et al.  Monoclonal gammopathy of undetermined significance (MGUS) : premyelomaの確立へ , 2002 .